A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
Terminated · Phase 2 · NCT05941442
Conditions: Panic Disorder
At a glance
- Research payments reported, 2025
- $810,097
- U.S. investigators named
- 28
- Sites paid
- 26
- Planned or actual enrollment
- 80
About the trial
- Sponsor
- AbbVie
- Tested
- Darigabat (drug), Placebo (drug)
- Dates
- Started 2023-07-31; completion 2025-03-31
- Results posted
- Yes
The purpose of this trial is to measure the efficacy, safety, and tolerability of darigabat (25 milligrams \[mg\] twice daily \[BID\]) compared with placebo in participants with panic disorder.
From ClinicalTrials.gov, last updated 2026-05-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $810,097 in research payments for this study in 2025 (152 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alyssa Boschen, PA-C Physician Assistants · Phoenix, AZ
- Gustavo Alva, M.D. Psychiatry · Orange, CA
- Evagelos Coskinas, M.D. Psychiatry · Costa Mesa, CA
- Ira Glick Psychiatry · Stanford, CA
- Sarbani Maitra, M.D. Psychiatry · Fairfield, CA
- Lara G. Shirikjian, D.O. Psychiatry · Torrance, CA
- Sherry Soefje, M.D. Psychiatry · Oceanside, CA
- Lazaro H. Cordoves, M.D. Psychiatry · Hialeah, FL
- Rosa M. Suarez, MD General Practice · Coral Gables, FL
- Yael R. Elfassy, M.D. Pediatrics · Savannah, GA
- Kimball A. Johnson, MD Internal Medicine · Atlanta, GA
- Fareha N. Malik, MD Child & Adolescent Psychiatry · Elgin, IL
- Haydn M. Thomas, M.D. Psychiatry · Prairie Village, KS
- Darin D. Dougherty, MD Psychiatry · Boston, MA
- Eric J. Carbonell, M.D. Psychiatry · Festus, MO
- Rasheed A. Onafuye, M.D Psychiatry · Monroe, NC
- Michael A. Hassman, DO Family Medicine · Berlin, NJ
- Mustafa M. Rawaf, DO Psychiatry · Las Vegas, NV
- Elyssa L. Barron, M.D. Psychiatry · White Plains, NY
- Lemaire Pierre, M.D. Psychiatry · New York, NY
- Nick G. Vatakis, M.D. Specialist · New York, NY
- Inna N. Yuryev-golger, MD Psychiatry · Brooklyn, NY
- Marvin L. Peyton, M.D. Psychiatry · Oklahoma City, OK
- Shivkumar S. Hatti, MD., MBA Psychiatry · Media, PA
- Donald J. Garcia JR., MD Psychiatry · Austin, TX
- Rajinder Shiwach, MD Psychiatry · Desoto, TX
- Reid J. Robison, MD Psychiatry · Orem, UT
- James A. Knutson, M.D. Prescribing Psychologist · Kirkland, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Harmony Clincial Research LLC $333,632
- Ima Evaluations LLC DBA Ima Clinical Research $70,813
- Spri Clinical Trials LLC $60,202
- Excell Research $42,937
- Prolive Medical Research Corp $37,175
- Iresearch Atlanta LLC $30,371
- Iresearch Savannah LLC $28,223
- Revive Research Institute Inc $24,740
- Eastside Therapeutic Resource Inc DBA Core Clinical Research $23,713
- Atlanta Center for Medical Research LLC $20,326
- Donald J Garcia MD $15,783
- Pioneer Clinical Research Ny LLC $15,260
- Sp Research PLLC DBA Rivus Wellness and Research Institute $14,257
- Pns Clinical Research LLC DBA Atp Clinical Research $13,090
- Integrative Clinical Trials LLC $11,670
- Insite Clinical Research LLC $10,175
- Lumos Clinical Research Center LLC $9,202
- Interspond $8,850
- Sunwise Clinical Research LLC $8,135
- Clinical Innovations Inc DBA Citrials $6,298
- Monroe Biomedical Research LLC $6,060
- Boston Clinical $4,535
- Collaborative Neuroscience Research LLC $4,416
- Hassman Research Institute $4,221
- Suburban Research Associates Inc $3,600
- Cedar Clinical Research $2,415
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.